{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"3.7","value":"3.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475 given intravenously at a fixed dose of 200mg every 3 weeks for up to 36 cycles\n\nMK-3475","id":"OG000","title":"Treatment"},{"description":"MK-3475 is given intravenously at a fixed dose of 200mg every 3 weeks Copanlisib is given intravenously at RP2D determined from Phase I study\n\nMK-3475\n\nCopanlisib","id":"OG001","title":"Combination"}],"paramType":"MEDIAN","populationDescription":"Study did not progress to portion with combination of pembrolizumab and copanlisib","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}